Business
Cerus Corporation Announces Symposium and Abstracts at the 38th International Congress of the International Society of Blood Transfusion
Symposium and Abstracts Highlight Data from Real-world Implementation and Utilization of INTERCEPT Platelets and Plasma as well as from Red Blood Cell and
About this update from Cerus Corporation
[{"type":"text","content":"\nSymposium and Abstracts Highlight Data from Real-world Implementation and Utilization of INTERCEPT Platelets and Plasma as well as from Red Blood Cell and LED Illuminator Programs\n\n\n CONCORD, Calif.--(BUSINESS WIRE)--\nCerus Corporation (Nasdaq:CERS) today announced a lunch symposium and selection of abstracts at the 38th International Congress of the International Society of Blood Transfusion (ISBT), taking place in Barcelona, Spain, from June 23 through June 27. Transfusion medicine experts and professionals from around the world attend the ISBT Congress.\n\n\nThe following is a list of selected presentations and abstracts of interest for Cerus. All presentation times are listed in Central European Summer Time (CEST). The full program of Cerus-related abstracts can be found at the following link: https://interceptbloodsystem.com/sites/default/files/resources/2024_isbt_abstractbook_final.pdf.\n\n\nOral Presentations\n\n\n\nThursday, June 27, 2024 – 12:30 p.m. – Cerus Lunch Symposium – Pathogen Inactivation: Further evidence for implementation\n\n\nThe natural virome and pandemic potential: Disease X\n\n\n\nComparison of clinical outcomes in cardiac surgery, using INTERCEPT platelets and conventional platelets\n\n\n\nBenefits and challenges of implementing pathogen inactivation methods – the importance of high quality randomized clinical studies\n\n\n\n\n\n\nThursday, June 27, 2024 – 11:15 a.m. – Quantifying Residual Red Blood Cells in Platelet and Plasma Components: Flow Cytometry and a Visual Inspection Tool Support Implementation of Pathogen Inactivation\n\n\n\nPoster Presentations\n\n\nHeld between Monday, June 24 and Thursday, June 27, 2024\n\n\n\nCold-Storage of Amotosalen-UVA Pathogen-Reduced Buffy-Coat Platelet Concentrates for Up to 21 Days: Biochemical and Functional Characterization, and Identification of Platelet Subpopulations\n\n\n\nSafety of Amotosalen/UVA Platelets and Plasma Transfused In Routine Clinical Use: Real World Evidence From 2 Large European Transfusion Medicine Centers, 2019-2022\n\n\n\nIntroduction of 7-Day Amotosalen/UVA Pathogen Reduced Platelets In Honduras: Impact on Platelet Availability In a Lower Middle Income Country\n\n\n\nAmotosalen-UVA Pathogen Reduced Plasma, Cryoprecipitate Reduced (PRPCR): An Optimized Cost-Effective Component for Therapeutic Plasma Exchange\n\n\n\nDevelopment of a...